Results 181 to 190 of about 132,265 (338)

Epidemiology and characteristics of validated mixed phenotype acute leukaemia-A comprehensive nationwide Danish cohort study. [PDF]

open access: yesBr J Haematol
Christensen LM   +11 more
europepmc   +1 more source

Correction to: Phenotypic, Genetic, and Cytogenetic Evidence of Hybridization between Species of Trans-Andean Tamarins (Genus Saguinus) [PDF]

open access: bronze, 2019
Iván Darío Soto‐Calderón   +5 more
openalex   +1 more source

Importance of SUMOylation Consensus Sequence of MAFK in Regulating EMT, Tumor Growth, Stemness, and Drug Resistance

open access: yesCancer Science, EarlyView.
In this study, we focused on SUMOylation, a posttranslational modification, and investigated the importance of its consensus sequence in MAFK. We demonstrated that the non‐SUMOylation mimic mutant MAFK (EA) impairs MAFK‐induced EMT, cellular migration and invasion, tumor and sphere formation, acquisition of stem‐like properties, and drug resistance ...
Thuy Linh Dang Cao   +7 more
wiley   +1 more source

Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment. [PDF]

open access: yesLeukemia
Voss RK   +28 more
europepmc   +1 more source

Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the Société Française de Greffe de Moelle et Thérapies Cellulaires

open access: green, 2015
Jordan Gauthier   +17 more
openalex   +1 more source

Real‐world experience with CPX‐351 for secondary acute myeloid leukaemia: Comparison with FLAG‐IDA in a propensity score matching analysis

open access: yes
British Journal of Haematology, EarlyView.
Maria Agustina Perusini   +19 more
wiley   +1 more source

Frontline ATRA‐ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG‐APL2017 Trial

open access: yesCancer Science, EarlyView.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy